Literature DB >> 11358425

Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment.

P J Sime1, K M O'Reilly.   

Abstract

Tissue fibrosis can lead to significant organ dysfunction and resulting patient morbidity and mortality. Unfortunately, the therapeutic repertoire is currently limited, nonspecific, and largely ineffective. While the pathogenesis is incompletely understood, evidence is accumulating that immune and cytokine mediated mechanisms are critical. In this review, data will be provided to support the role of Type 2 cytokines in the pathogenesis of fibrosis. The importance of the role of the pro-fibrogenic cytokine TGF-beta and CD40-CD40 ligand mediated fibroblast activation will also be evaluated. Finally, novel therapeutic options based on inhibiting these pathways will be described. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358425     DOI: 10.1006/clim.2001.5008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  109 in total

Review 1.  Targeting CD40L: a promising therapeutic approach.

Authors:  Dimitris Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

3.  PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice.

Authors:  Jin-Xia Zhai; Zhao-Xiang Zhang; Ya-Juan Feng; Shu-Shu Ding; Xing-Hua Wang; Li-Wei Zou; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-02-09       Impact factor: 2.316

Review 4.  Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling.

Authors:  Chun Geun Lee; Hye-Ryun Kang; Robert J Homer; Geoffrey Chupp; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2006-07

Review 5.  Extracellular superoxide dismutase in pulmonary fibrosis.

Authors:  Fei Gao; Vuokko L Kinnula; Marjukka Myllärniemi; Tim D Oury
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 6.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

7.  IPF pathogenesis is dependent upon TGFβ induction of IGF-1.

Authors:  Danielle M Hernandez; Jeong-Han Kang; Malay Choudhury; Mahefatiana Andrianifahanana; Xueqian Yin; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

8.  Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Authors:  Olga B Garbuzenko; Vera Ivanova; Vladislav Kholodovych; David C Reimer; Kenneth R Reuhl; Edvard Yurkow; Derek Adler; Tamara Minko
Journal:  Nanomedicine       Date:  2017-04-19       Impact factor: 5.307

9.  Enhanced expression of interleukin-18 in serum and pancreas of patients with chronic pancreatitis.

Authors:  Alexander Schneider; Stephan-L Haas; Ralf Hildenbrand; Sören Siegmund; Iris Reinhard; Helmut Nakovics; Manfred-V Singer; Peter Feick
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

10.  Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Authors:  Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Eur J Pharm Biopharm       Date:  2012-12-08       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.